INVO Fertility, Inc. 8-K

What Happened

• INVO Fertility (IVF) filed an 8-K (dated Jan 6, 2026) announcing executive changes effective December 30, 2025. Terah Krigsvold was appointed chief financial officer. Andrea Goren resigned as CFO and was appointed chief business officer.
• Both Krigsvold and Goren will have annual base salaries of $250,000 and are eligible for performance bonuses up to 50% of base salary and equity grants under the company’s 2019 Stock Incentive Plan. The filing includes amended employment agreements for each executive and a company press release dated December 30, 2025.

Key Details

• Effective date: December 30, 2025 (appointment and role change).
• New CFO: Terah Krigsvold, age 43; company controller since Dec 3, 2020; BS (2014) and MS (2016) in Accounting from Western Governors University.
• Former CFO/new CBO: Andrea Goren, age 58; served as CFO since June 14, 2021; 30+ years of financial and capital markets experience (MBA, Columbia Business School).
• Compensation: $250,000 base salary each; bonuses up to 50% of base pay; eligible for stock awards under the 2019 Stock Incentive Plan.
• Filing includes: Krigsvold Amended and Restated Employment Agreement (Exhibit 10.1), Goren Amendment (Exhibit 10.2) and press release (Exhibit 99.1).

Why It Matters

• Leadership continuity: The CFO role is being filled internally by the long-time controller, which may support continuity in financial operations and reporting.
• Cost and incentives: Pay structures (equal base pay and similar bonus opportunity) align the new CFO and the transitioned CBO with performance and equity incentives, important for shareholder alignment.
• Signal to investors: The company formalized the change via amended employment agreements and a press release, indicating a planned executive realignment rather than a sudden departure.